Jianghua Ran - Concepedia

Author

Jianghua Ran

Kunming Medical University

Also Known As

J.H. Ran, Jiang-Hua Ran, Jiang-hua Ran, Jianghua Ran, Jiang‐Hua Ran, Jiantao Ran, Sheng-ning Zhang, Yu Zhang

Publications

676

Citations

H-Index

Concepts

All Affiliations

Kunming Medical University The First Hospital of Kunming First Affiliated Hospital of Kunming Medical University

About

Jianghua Ran is an author at Kunming Medical University specializing in medicine, hepatology, and liver.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	70
2	Cell Biology	2	2	43
3	Hepatology	2	2	41
4	Immunology	2	2	43
5	Pathology	2	2	41

Jianghua Ran

Publications

562

Citations

H-Index

Page 1

	Year	Citations
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma Zongqiang Hu, Gang Chen, Yingpeng Zhao, Molecular Cancer	2023	282
Long noncoding RNA NEAT1 promotes cell proliferation and invasion by regulating hnRNP A2 expression in hepatocellular carcinoma cells Yuanyi Mang, Li Li, Jianghua Ran, OncoTargets and Therapy	2017	73
Interferon-α2b gene-modified human bone marrow mesenchymal stem cells inhibit hepatocellular carcinoma by reducing the Notch1 levels Yanjun Su, Ruochuan Cheng, Jianming Zhang, Life Sciences Tumor BiologyMedicineStem CellsImmunologyStem Cell Research	2015	29
Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3 Zongqiang Hu, Yingpeng Zhao, Laibang Li, Molecular Biology Reports	2023	28
Establishment of a Standardized Liver Fibrosis Model with Different Pathological Stages in Rats Li Li, Zongqiang Hu, Wen Li, Gastroenterology Research and Practice Liver FibrosisPathologyCirrhosisHepatic DisordersDifferent Pathological Stages	2012	27
MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24 Zongqiang Hu, Yingpeng Zhao, Yuanyi Mang, Life Sciences	2023	25
Exercise activates Sirt1-mediated Drp1 acetylation and inhibits hepatocyte apoptosis to improve nonalcoholic fatty liver disease Zongqiang Hu, Hongyu Zhang, Yi‐Ting Wang, Lipids in Health and Disease	2023	23
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying <i>FGFR2</i> fusions or rearrangements: A phase <scp>II</scp> study Guo‐Ming Shi, Xiaoyong Huang, Tian‐Fu Wen, Cancer Medicine	2022	20
Integrated Bioinformatics Analysis for the Screening of Hub Genes andTherapeutic Drugs in Hepatocellular Carcinoma Qiuming Su, Wang Li, Xibing Zhang, Current Pharmaceutical Biotechnology	2022	19
Human Hepatocyte Growth Factor (hHGF)-Modified Hepatic Oval Cells Improve Liver Transplant Survival Li Zhu, Juan Chen, Li Li, PLoS ONE ImmunologyPathologyLiver FunctionCholangiopathiesRegenerative Medicine	2012	14

Page 1